IL6R
Overview
IL6R (Interleukin 6 Receptor) is the cell-surface receptor for IL-6, activating downstream JAK/STAT3 signalling. In hepatocellular carcinoma (HCC), IL6R is altered at ~1% frequency and is an FDA-targetable alteration. The IL6/JAK/STAT pathway, which includes IL6R and IL6ST, is altered in 9% of HCC.
Alterations observed in the corpus
- IL6R alteration in ~1% of HCC cases (243-case European WES cohort); listed as FDA-targetable; part of the IL6/JAK/STAT pathway altered in 9% of HCC. PMID:25822088
Cancer types (linked)
- HCC: Altered in ~1% of cases; part of IL6/JAK/STAT pathway (9% overall pathway alteration rate); nominated as FDA-targetable. PMID:25822088
Co-occurrence and mutual exclusivity
- Co-occurs with IL6ST in the IL6/JAK/STAT pathway in HCC; IL6ST mutations are restricted to HCC of unknown etiology while IL6R was not noted to have a specific etiologic enrichment. PMID:25822088
Therapeutic relevance
- IL6R alteration (~1% of HCC) is designated FDA-targetable in the 243-case HCC cohort; tocilizumab (anti-IL6R) and related agents are candidates. PMID:25822088
Open questions
- Functional consequences of somatic IL6R mutations in HCC and whether they activate or abrogate IL6 signalling are not defined in the corpus. PMID:25822088
Sources
This page was processed by crosslinker on 2026-05-14.